Data extraction After finishing the study selection, the final studies (randomized and non-randomized) underwent data extraction to summarize the following variables: author, publication year, type of study, population, intervention, control, type of surgery and procedure, and the result of outcomes of interest
Additional: Recent coverage (e.g., NY Post Feb 2026 on discontinuation signals), company updates.
doi:10.1096/fj.02-0456fje Schnedl WJ, Enko D
Doses Per Vial 5mg vial: At 2.5mg/week = 2 weeks At 5mg/week = 1 week 10mg vial: At 2.5mg/week = 4 weeks At 5mg/week = 2 weeks At 7.5mg/week = 1.3 weeks At 10mg/week = 1 week 15mg vial: At 2.5mg/week = 6 weeks At 5mg/week = 3 weeks At 10mg/week = 1.5 weeks At 15mg/week = 1 week A 10mg vial covers the first month of a standard escalation at 2.5mg/week

References References CJC-1295 (No DAC) in healthy adults prolonged GH/IGF-1 stimulation (RCT, JCEM) CJC-1295 preclinical analog work increased GH exposure (rat) Ipamorelin first selective GH secretagogue with minimal ACTH/cortisol (Eur J Endocrinol) Ipamorelin PK/PD in healthy volunteers Combined GHRH + GHRP-2 synergistic GH release (children, JCEM) Combined GHRH + GHRP enhanced GH responses (acromegaly) GH pulsatility & hepatic signaling STAT5b biology (mechanistic) Preserved efficacy of GHRH/GHRP-2 robust GH secretion (open access) Synonyms: CJC + Ipamorelin blend, GHRH + GHRP stack, Mod GRF (1-29) + Ipamorelin, Growth hormone combo, GH synergy blend